IT1269826B - Uso di antagonisti degli oppiacei e di sali di calcio per la preparazione di medicamenti per il trattamento di forme patologiche endorfino-mediate - Google Patents

Uso di antagonisti degli oppiacei e di sali di calcio per la preparazione di medicamenti per il trattamento di forme patologiche endorfino-mediate

Info

Publication number
IT1269826B
IT1269826B ITMI941048A ITMI941048A IT1269826B IT 1269826 B IT1269826 B IT 1269826B IT MI941048 A ITMI941048 A IT MI941048A IT MI941048 A ITMI941048 A IT MI941048A IT 1269826 B IT1269826 B IT 1269826B
Authority
IT
Italy
Prior art keywords
preparation
treatment
antagonists
optiacean
endorphine
Prior art date
Application number
ITMI941048A
Other languages
English (en)
Inventor
Paolo Minoia
Raffaele Scioraci
Original Assignee
Paolo Minoia
Sciorsci Raffaele
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Paolo Minoia, Sciorsci Raffaele filed Critical Paolo Minoia
Publication of ITMI941048A0 publication Critical patent/ITMI941048A0/it
Priority to ITMI941048A priority Critical patent/IT1269826B/it
Priority to KR1019960706602A priority patent/KR970703148A/ko
Priority to AU26149/95A priority patent/AU708778B2/en
Priority to JP7530058A priority patent/JPH10500423A/ja
Priority to PCT/EP1995/001931 priority patent/WO1995031985A2/en
Priority to HU9603228A priority patent/HUT77920A/hu
Priority to CA2190943A priority patent/CA2190943C/en
Priority to EP95920851A priority patent/EP0760661B1/en
Priority to ES95920851T priority patent/ES2128735T3/es
Priority to AT95920851T priority patent/ATE175114T1/de
Priority to DK95920851T priority patent/DK0760661T3/da
Priority to CN95193758A priority patent/CN1083264C/zh
Priority to US08/737,902 priority patent/US5811451A/en
Priority to DE69507029T priority patent/DE69507029T2/de
Publication of ITMI941048A1 publication Critical patent/ITMI941048A1/it
Application granted granted Critical
Publication of IT1269826B publication Critical patent/IT1269826B/it
Priority to JP2006303392A priority patent/JP2007210995A/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)

Abstract

Si descrive l'uso combinato di antagonisti degli oppiacei e di sali di calcio per la preparazione di medicamenti per il trattamento di forme patologiche endorfino - mediate.
ITMI941048A 1994-05-24 1994-05-24 Uso di antagonisti degli oppiacei e di sali di calcio per la preparazione di medicamenti per il trattamento di forme patologiche endorfino-mediate IT1269826B (it)

Priority Applications (15)

Application Number Priority Date Filing Date Title
ITMI941048A IT1269826B (it) 1994-05-24 1994-05-24 Uso di antagonisti degli oppiacei e di sali di calcio per la preparazione di medicamenti per il trattamento di forme patologiche endorfino-mediate
ES95920851T ES2128735T3 (es) 1994-05-24 1995-05-22 Composiciones farmaceuticas que comprenden un antagonista de opiaceos y de sales de calcio y su uso para el tratamiento de patologias en las que intervienen las endorfinas.
DK95920851T DK0760661T3 (da) 1994-05-24 1995-05-22 Farmaceutiske sammensætninger omfattende en opiat-antagonist og calciumsalte, deres anvendelse til behandling af endorfin-m
JP7530058A JPH10500423A (ja) 1994-05-24 1995-05-22 アヘン剤拮抗物質およびカルシウム塩を含む薬剤組成物、エンドルフィン介在病状の治療のためのこれらの使用法
PCT/EP1995/001931 WO1995031985A2 (en) 1994-05-24 1995-05-22 Pharmaceutical compositions comprising an opiate antagonist and calcium salts, their use for the treatment of endorphin-mediated pathologies
HU9603228A HUT77920A (hu) 1994-05-24 1995-05-22 Opiát antagonistát és kalciumsókat tartalmazó gyógyászati készítmények és alkalmazásuk
CA2190943A CA2190943C (en) 1994-05-24 1995-05-22 Pharmaceutical compositions comprising an opiate antagonist and calcium salts, their use for the treatment of endorphin-mediated pathologies
EP95920851A EP0760661B1 (en) 1994-05-24 1995-05-22 Pharmaceutical compositions comprising an opiate antagonist and calcium salts, their use for the treatment of endorphin-mediated pathologies
KR1019960706602A KR970703148A (ko) 1994-05-24 1995-05-22 아편 길항제와 칼슘염으로 구성된 의약 조성물과 그의 엔돌핀-매개 질병 치료용 용도(pharmaceutical compositions comprising an opiateantagonist and calcium salts, their use for the treatment of endorphin-mediated pathologies)
AT95920851T ATE175114T1 (de) 1994-05-24 1995-05-22 Pharmazeutische zusammensetzungen enthaltend einen opiat antagonist und calcium salze, ihre verwendung zur behandlung von endorphin- vermittelten krankheiten
AU26149/95A AU708778B2 (en) 1994-05-24 1995-05-22 Pharmaceutical compositions comprising an opiate antagonist and calcium salts, their use for the treatment of endorphin-mediated pathologies
CN95193758A CN1083264C (zh) 1994-05-24 1995-05-22 含有鸦片样拮抗剂和钙盐的药物组合物及其在治疗内啡肽介导的疾病中的应用
US08/737,902 US5811451A (en) 1994-05-24 1995-05-22 Pharmaceutical compositions comprising an opiate antagonist and calcium salts, their use for the treatment of endorphin-mediated pathologies
DE69507029T DE69507029T2 (de) 1994-05-24 1995-05-22 Pharmazeutische zusammensetzungen enthaltend einen opiat antagonist und calcium salze, ihre verwendung zur behandlung von endorphin-vermittelten krankheiten
JP2006303392A JP2007210995A (ja) 1994-05-24 2006-11-08 アヘン剤拮抗物質およびカルシウム塩を含む薬剤組成物、エンドルフィン介在病状の治療のためのこれらの使用法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITMI941048A IT1269826B (it) 1994-05-24 1994-05-24 Uso di antagonisti degli oppiacei e di sali di calcio per la preparazione di medicamenti per il trattamento di forme patologiche endorfino-mediate

Publications (3)

Publication Number Publication Date
ITMI941048A0 ITMI941048A0 (it) 1994-05-24
ITMI941048A1 ITMI941048A1 (it) 1995-11-24
IT1269826B true IT1269826B (it) 1997-04-15

Family

ID=11368969

Family Applications (1)

Application Number Title Priority Date Filing Date
ITMI941048A IT1269826B (it) 1994-05-24 1994-05-24 Uso di antagonisti degli oppiacei e di sali di calcio per la preparazione di medicamenti per il trattamento di forme patologiche endorfino-mediate

Country Status (14)

Country Link
US (1) US5811451A (it)
EP (1) EP0760661B1 (it)
JP (2) JPH10500423A (it)
KR (1) KR970703148A (it)
CN (1) CN1083264C (it)
AT (1) ATE175114T1 (it)
AU (1) AU708778B2 (it)
CA (1) CA2190943C (it)
DE (1) DE69507029T2 (it)
DK (1) DK0760661T3 (it)
ES (1) ES2128735T3 (it)
HU (1) HUT77920A (it)
IT (1) IT1269826B (it)
WO (1) WO1995031985A2 (it)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6103258A (en) * 1996-04-12 2000-08-15 Simon; David Lew Salts and bases of the 17-(Cyclopropylmethyl)-4,5 alpha-epoxy-6-Methylenemorphinan-3,14 diol molecule for optimizing dopamine homeostasis during administration of opioid analgesics
US20030158220A1 (en) * 1997-11-03 2003-08-21 Foss Joseph F. Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
US6559158B1 (en) 1997-11-03 2003-05-06 Ur Labs, Inc. Use of methylnaltrexone and related compounds to treat chronic opioid use side affects
US6274591B1 (en) * 1997-11-03 2001-08-14 Joseph F. Foss Use of methylnaltrexone and related compounds
US6451806B2 (en) 1999-09-29 2002-09-17 Adolor Corporation Methods and compositions involving opioids and antagonists thereof
US6469030B2 (en) 1999-11-29 2002-10-22 Adolor Corporation Methods for the treatment and prevention of ileus
WO2002098422A1 (en) * 2001-06-05 2002-12-12 University Of Chicago Use of methylnaltrexone to treat immune suppression
US7968119B2 (en) * 2001-06-26 2011-06-28 Farrell John J Tamper-proof narcotic delivery system
US20030130171A1 (en) * 2001-10-30 2003-07-10 Schoenhard Grant L. Inhibitors of ABC drug transporters in multidrug resistant microbial cells
US20040259898A1 (en) * 2002-02-04 2004-12-23 Jonathan Moss Use of methylnaltrexone in treating gastrointestinal dysfunction in equines
US20050011468A1 (en) * 2002-02-04 2005-01-20 Jonathan Moss Use of methylnaltrexone in treating gastrointestinal dysfunction in equines
US20060177381A1 (en) * 2002-02-15 2006-08-10 Howard Brooks-Korn Opiopathies
GB0212405D0 (en) * 2002-05-29 2002-07-10 Insignion Holdings Ltd Composition and its therapeutic use
MXPA05010821A (es) * 2003-04-08 2006-03-30 Progenics Pharm Inc Terapia de combinacion para constipacion que comprende un laxante y un antagonista opioide periferico.
JP2006522817A (ja) * 2003-04-08 2006-10-05 プロジェニックス ファーマシューティカルズ，インコーポレーテッド 過敏性腸症候群を処置するための末梢オピオイドアンタゴニスト、特にメチルナルトレキソンの使用
PL2368554T3 (pl) 2003-04-08 2015-05-29 Progenics Pharm Inc Preparaty farmaceutyczne zawierające metylonaltrekson
US20060069086A1 (en) * 2004-09-23 2006-03-30 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
AU2006206454A1 (en) * 2005-01-20 2006-07-27 Progenics Pharmaceuticals, Inc. Use of methylnaltrexone and related compounds to treat post-operative gastrointestinal dysfunction
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
MX2007010833A (es) 2005-03-07 2009-02-17 Univ Chicago Uso de antagonistas opioides para atenuar proliferacion y migracion de células endoteliales.
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
KR20060119373A (ko) * 2005-05-20 2006-11-24 엘지전자 주식회사 컴퓨터 시스템과 시스템 소프트웨어 설치방법 및 휴대용컴퓨터의 소프트웨어 설치방법
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
TW200815451A (en) * 2006-08-04 2008-04-01 Wyeth Corp 6-carboxy-normorphinan derivatives, synthesis and uses thereof
US7820689B2 (en) * 2006-08-10 2010-10-26 Hua-Lin Wu Methods and compositions for preventing or treating cardiovascular disease
MX2009010550A (es) 2007-03-29 2009-12-14 Progenics Pharm Inc Formas de cristal de bromuro de (r)-n-metilnaltrexona y uso de las mismas.
JP5469593B2 (ja) 2007-03-29 2014-04-16 ワイス・エルエルシー 末梢性オピオイド受容体アンタゴニストおよびその使用
WO2008121348A2 (en) 2007-03-29 2008-10-09 Progenics Pharmaceuticals, Inc. Peripheral opioid receptor antagonists and uses thereof
US20090006902A1 (en) * 2007-06-29 2009-01-01 International Business Machines Corporation Methods, systems, and computer program products for reporting fru failures in storage device enclosures
CA2702680A1 (en) * 2007-10-18 2009-04-23 Aiko Biotechnology Combination analgesic employing opioid and neutral antagonist
US8748448B2 (en) 2007-10-18 2014-06-10 Aiko Biotechnology Combination analgesic employing opioid agonist and neutral antagonist
AU2008349873B2 (en) 2008-02-06 2014-02-13 Progenics Pharmaceuticals, Inc. Preparation and use of (R),(R)-2,2'-bis-methylnaltrexone
CA2719134C (en) 2008-03-21 2015-06-30 The University Of Chicago Treatment with opioid antagonists and mtor inhibitors
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
WO2012079154A1 (en) * 2010-12-14 2012-06-21 Dalhousie University Selective estrogen receptor modulators
RU2488404C1 (ru) * 2012-03-27 2013-07-27 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт кардиологии" Сибирского отделения Российской академии медицинских наук Средство, увеличивающее устойчивость сердца к ишемическим и последующим реперфузионным повреждениям

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1593191A (en) * 1977-03-23 1981-07-15 Reckitt & Colmann Prod Ltd Derivatives of morphine
IT1096665B (it) * 1978-06-14 1985-08-26 Tecnofarmaci Spa Composizione farmaceutica per la terapia di stati di frigidita' ed impotenza
NL8700842A (it) * 1987-04-10 1988-11-01 Duphar Int Res
JPH0653683B2 (ja) * 1988-07-14 1994-07-20 ザ ロックフェラー ユニバーシティ 慢性痛あるいは慢性咳を治療する経口用組成物
JP3160862B2 (ja) * 1990-11-15 2001-04-25 雪印乳業株式会社 骨強化食品、飼料及び医薬
US5159081A (en) * 1991-03-29 1992-10-27 Eli Lilly And Company Intermediates of peripherally selective n-carbonyl-3,4,4-trisubstituted piperidine opioid antagonists
JPH05213763A (ja) * 1992-02-10 1993-08-24 Sanwa Kagaku Kenkyusho Co Ltd 易吸収活性化カルシウム製剤
GB2272375B (en) * 1992-04-10 1996-02-14 Vnii Med Polimerov Pharmaceutical composition

Also Published As

Publication number Publication date
ITMI941048A0 (it) 1994-05-24
US5811451A (en) 1998-09-22
CA2190943C (en) 2010-06-22
CN1151116A (zh) 1997-06-04
HU9603228D0 (en) 1997-01-28
EP0760661A1 (en) 1997-03-12
WO1995031985A2 (en) 1995-11-30
DK0760661T3 (da) 1999-08-30
ATE175114T1 (de) 1999-01-15
DE69507029D1 (de) 1999-02-11
CA2190943A1 (en) 1995-11-30
EP0760661B1 (en) 1998-12-30
AU708778B2 (en) 1999-08-12
DE69507029T2 (de) 1999-07-15
ES2128735T3 (es) 1999-05-16
CN1083264C (zh) 2002-04-24
WO1995031985A3 (en) 1996-01-04
KR970703148A (ko) 1997-07-03
JP2007210995A (ja) 2007-08-23
HUT77920A (hu) 1998-10-28
JPH10500423A (ja) 1998-01-13
ITMI941048A1 (it) 1995-11-24
AU2614995A (en) 1995-12-18

Similar Documents

Publication Publication Date Title
ITMI941048A0 (it) Uso di antagonisti degli oppiacei e di sali di calcio per la preparazione di medicamenti per il trattamento di forme patologiche endorfino-mediante
ES2157344T3 (es) Pirrolo(2,3-d)pirimidinas y su uso.
IT1190466B (it) Procedimento di trattamento per forme farmaceutiche di dosaggio rivestite per ridurne la collosita'
EP1007148A4 (en) METHOD FOR SETTING THE STIMULATION LOCATION OF ELECTRICALLY EXPENSIBLE TISSUE
IT8620766A0 (it) Mescole-madri per l'opacizzazione di poliammidi.
IT1240360B (it) Uso di un derivato dell'1alfa-idrossivitamina d per la preparazione di un medicamento per il trattamento dell' iperparatiroidismo
BR9507771A (pt) Processos para preparação de ácido 1-Butil-2-(2'-(2H-Tetratozol-5-IL)-Bifenil-4-Ilmetil(-1H-Indol-3-Carboxílico
DE3650647D1 (de) Arzneimittel zur Behandlung von Anxietas
BR9813208A (pt) Antagonista receptor de vitronectina
DE69434777D1 (de) Verwendung von Relaxin zur Herstellung von therapeutischen Mitteln
SE9402880D0 (sv) New peptide derivatives
IT1281267B1 (it) Dispositivo per l'agugliatura di ovatte.
IT1289303B1 (it) Apparecchiatura per l'orientamento ed il supporto di strumenti ad uso chirurgico
IS4597A (is) Ný lyfjafræðileg notkun AII-viðtaka mótlyfja
IT1281218B1 (it) Dispositivo per l'agugliatura di ovatte.
FI953720A0 (fi) Neurotensiiniantagonistien käyttö diureettietan lääkkeiden valmistamiseksi
IT8922246A0 (it) Procedimento di preparazione di 3-ciano-3,5,5'-trimetil-1-cicloesanone
EP0339600A3 (en) Polycyclic amine derivatives useful as cerebrovascular agents
MD283F1 (ro) Compozitie de ingrediente pentru balsamul tonifiant "legenda"
ITMI931371A1 (it) Procedimento per la preparazione dell'erdosteina
IT8848523A0 (it) Procedimento integrato per la fitodepurazione di acque reflue
IT1273509B (it) Composti azolici ad attivita' antimicotica per uso umano e veterinario
DE69625379D1 (de) Salze des n-[4-oxo-2-(1h-tetrazoyl-5-yl)-4h-1-benzopyran-8-yl]-4-(4-phenylbutoxy)benzamids
ITMI911253A0 (it) Macchina per il trattamento e l'erogazione di impasti cementizi, particolarmente per la realizzazione di intonaci
IT1275457B (it) Utilizzo di sequenze di endorfina per la preparazione di un medicamento immunosoppressore privo di attivita' oppiacea

Legal Events

Date Code Title Description
0001 Granted
TA Fee payment date (situation as of event date), data collected since 19931001

Effective date: 19970529